Previous 10 | Next 10 |
- Favorable safety and tolerability profile - Superior antiviral activity with ABI-H0731 in combination with nucleos(t)ide therapies - Selected for inclusion in “Best of ILC” presentation - Company to host conference call Monday, April 15, 2019 at 8am EDT SAN FRANC...
Most developers of therapies to treat nonalcoholic steatohepatitis (NASH) are under modest pressure as investors remain unimpressed with the initial announcements from The International Liver Congress in Vienna. More news on: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Enanta P...
Thinly traded Assembly Biosciences (NASDAQ: ASMB ) is down 3% premarket on light volume in response to new data on its next-generation core protein inhibitors ABI-H2158 and ABI-H3733. The results are being presented at The International Liver Congress in Vienna. More news on:...
Phase 1a study of ABI-H2158 demonstrated safety, tolerability and achievement of target liver concentrations ABI-H3733 demonstrated enhanced potency in preclinical studies HBV cccDNA shown to have a limited half-life, suggesting potential for curative treatment regimen Interi...
SAN FRANCISCO, March 27, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the acceptance of oral and po...
Gainers: ARTX +7.9% . IGC +7.4% . ASMB +5.7% . CTEK +4.9% . CFMS +4.6% . More news on: Arotech Corporation, India Globalization Capital, Inc., Assembly Biosciences, Inc., Stocks on the move, Read more ...
SAN FRANCISCO, March 13, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Derek Small, Assembly...
Assembly Biosciences (NASDAQ: ASMB ): Q4 GAAP EPS of -$1.03 misses by $0.08 . More news on: Assembly Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN FRANCISCO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today reported financial results for the fourt...
NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Brighthouse Financial, Inc. (NASDAQ:BHF), BioMarin Pharmaceutical Inc. (NA...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...